David Moadel

David Moadel

InvestorPlace Contributor

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

Snowflake Stock: A Sleeping Giant Ready to Erupt with 30% Gains

By David Moadel, InvestorPlace Contributor

Snowflake stock will only trade at a deep discount for so long, as Snowflake will certainly survive its current reputational issues.

35% Surge Just the Beginning? Alnylam’s Stock Poised for Massive Gains on Heart Drug Success.

By David Moadel, InvestorPlace Contributor

Alnylam Pharmaceuticals stock recently popped and could continue to move higher on Alnylam Pharmaceuticals' cardiovascular drug announcement.

Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble

By David Moadel, InvestorPlace Contributor

G1 Therapeutics stock is highly volatile, and investors should be wary now as G1 Therapeutics recently failed to achieve a clinical goal.

Stay Away: Why Ginkgo Bioworks Stock Is Not for the Faint-Hearted

By David Moadel, InvestorPlace Contributor

Ginkgo Bioworks stock is down, but this doesn't mean it's a bargain as Ginkgo Bioworks faces a serious delisting threat.

Jim Cramer Doesn’t Like SoFi Stock. This Is Your Buy Signal.

By David Moadel, InvestorPlace Contributor

Don't listen to the SoFi stock bears and haters as SoFi Technologies' impressive financial performance speaks for itself.

Load More